Andres Pichon-Riviere - Vice-Chair (2010-2014)


Andrés Pichon-Riviere is the Executive Director of the Institute for Clinical Effectiveness and Health Policy (IECS - and Director of the Health Technology Assessment and Economic Evaluation area.
Dr. Pichon-Riviere is Professor of Public Health at the University of Buenos Aires and member of the Board of the Clinical Effectiveness Program, a Master’s program of the University of Buenos Aires, where he coordinates the courses of Biostatistics, Statistical Computing and Survival Analysis. Dr. Pichon-Riviere is Executive Board Member of LatinCLEN, the Latin American division of the International Clinical Epidemiology Network (INCLEN), and member of the Foundation Board of IC-Health (Initiative for Cardiovascular Health Research in the Developing Countries).
In 2008, Prof Pichon-Riviere was awarded the Global Health Leadership Award from the Global Health Research Initiative (IDRC, CIDA and CIHR from Canada) for his project “Improving equity and efficiency of health systems in Latin America: bridging research and policy in health resource allocation by strengthening capacity and application of Health Technology.

Vision for INAHTA:

Gender, ethnicity and socio-economic inequalities are widespread in Latin American health systems similarly to other low and middle income countries around the world. Given the constant evolution of new and inevitably more expensive treatments and diagnostics, by not reacting right away we will observe a continuous and growing inequity whereby a few will continue to access costly technologies of marginal benefit while most don’t even have access to basic and highly cost-effective care.

My carrier goal during the next years is to actively contribute to the achievement of more equitable and effective health systems in Latin America and other LMIC by collaborating in the promotion of HTA/EE, training investigators in HTA/EE, generating and facilitating the generation of local HTA/EE evidence, and encouraging explicit mechanisms for the incorporation of HTA/EE in the decision-making processes. To reach this aim I find it very important to promote a regional perspective of the problem, establishing networks of investigators and decision-makers and uniting efforts to confront shared problems.
INAHTA can play an important role for HTA in emerging economies. In this sense, there are significant opportunities for collaboration with other institutions and organizations such as WHO, HTAi, INCLEN Trust or EUnetHTA. As board member of INAHTA I will be glad to contribute to this effort. I will also push forward for the inclusion of different perspectives about efficiency-equity trade-offs in the global world, highlighting the views of developing countries.